Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
MWN-AI** Summary
Tiziana Life Sciences, a biotech firm renowned for its innovative immunomodulation therapies, is set to present at BIO-Europe 2025, which will take place in Vienna from November 3-5. The company’s management team, led by CEO Ivor Elrifi, will showcase their leading candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which represents a novel approach in treating neuroinflammatory and neurodegenerative diseases like non-active secondary progressive multiple sclerosis (na-SPMS), Multiple System Atrophy (MSA), and early Alzheimer’s disease.
Bio-Europe is a premier event aimed at fostering partnerships in the life sciences sector, anticipated to attract over 5,700 delegates. Tiziana's participation is strategically timed as they engage in one-on-one meetings with prominent biopharma executives and investors, highlighting the significance of partnerships in advancing their clinical pipeline. Tiziana is currently in a Phase 2 clinical trial for na-SPMS and MSA, and plans to initiate Phase 2 studies for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
Foralumab's unique nasal delivery system aims to enhance treatment efficacy and patient tolerability compared to traditional intravenous methods, potentially transforming standard treatment protocols in the neurological field. Tiziana's focus on intranasal delivery is not only innovative but could also address significant unmet medical needs.
Tiziana Life Sciences is committed to advancing its pipeline of therapies leveraging groundbreaking delivery technologies. Foralumab stands out as the only fully human anti-CD3 mAb in clinical development, with promising results observed in ongoing studies. This pioneering approach may redefine immunotherapy for treating chronic neurological conditions, positioning Tiziana favorably in the competitive biotech landscape.
MWN-AI** Analysis
Tiziana Life Sciences (Nasdaq: TLSA) is gaining significant attention as it prepares to present at BIO-Europe 2025 in Vienna, focusing on its groundbreaking intranasal foralumab, a fully human anti-CD3 monoclonal antibody. This innovative approach to immunotherapy has the potential to revolutionize treatment paradigms for patients with neuroinflammatory and neurodegenerative diseases, specifically targeting conditions such as non-active secondary progressive multiple sclerosis (na-SPMS) and early Alzheimer’s disease.
The company is currently involved in Phase 2 clinical trials for na-SPMS and Multiple System Atrophy (MSA), with promising data indicating patient stability or improvement within six months. Such results enhance the therapeutic profile of foralumab, particularly as it represents the only fully human anti-CD3 monoclonal antibody in clinical development. This could position Tiziana as a frontrunner in a niche but critical market segment, offering hope for patients where traditional IV methods have limitations.
Tiziana’s participation at BIO-Europe is paramount, not only for showcasing its advancements but also for establishing strategic partnerships that could bolster its research and development efforts. The conference, attended by over 5,700 delegates, offers ample opportunities for Tiziana to connect with biopharma executives and potential investors, critical for securing additional funding and collaborative opportunities to accelerate their pipeline.
Given Tiziana's commitment to novel therapies and the compelling clinical data emerging from their trials, the stock could present an appealing opportunity for investors looking to enter the biotech sector. As the landscape of immunotherapy continues to evolve, Tiziana's innovative nasal delivery system may set it apart from competitors, making it a stock to watch as it gears up for commercialization. Caution is advised, however, as the biotech sector can be highly volatile, making thorough research essential before investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria.
Tiziana’s management team, led by CEO Ivor Elrifi, will also engage in one-on-one partnering meetings with leading biopharma executives and investors. The Company’s presentation will focus on its innovative nasal delivery platform and lead candidate, intranasal foralumab—the only fully human anti-CD3 monoclonal antibody in clinical development. This proprietary approach aims to enhance efficacy, safety, and tolerability over traditional intravenous methods, targeting neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis (na-SPMS), Multiple System Atrophy (MSA), and early Alzheimer’s disease.
“We are excited to showcase Tiziana’s progress at BIO-Europe 2025, a pivotal forum for forging strategic partnerships that can accelerate our pipeline toward commercialization,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “Building on our ongoing Phase 2 clinical trials in na-SPMS and MSA, we are about to commence Phase 2 studies in early Alzheimer’s disease and in amyotrophic lateral sclerosis (“ALS”). We look forward to discussing how our intranasal foralumab can address unmet needs in immunotherapy and drive meaningful patient outcomes.”
BIO-Europe 2025 is expected to draw over 5,700 delegates from more than 60 countries, facilitating thousands of targeted partnering meetings. Tiziana’s participation underscores its commitment to advancing novel therapies that modulate immune responses through alternative delivery routes, potentially transforming treatment paradigms for chronic neurological conditions.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program ( NCT06802328 ) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis ( NCT06292923 ).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. [1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com .
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ**
What specific advancements or results regarding intranasal foralumab does Tiziana Life Sciences plc (TLSA) aim to present at BIO-Europe 2025 that could attract potential partners?
How does Tiziana Life Sciences plc (TLSA) plan to differentiate its intranasal foralumab delivery method from traditional intravenous therapies in the treatment of neuroinflammatory diseases?
With ongoing Phase 2 clinical trials in na-SPMS and MSA, how does Tiziana Life Sciences plc (TLSA) measure and define success in terms of patient outcomes during these studies?
What strategic partnerships is Tiziana Life Sciences plc (TLSA) looking to establish at BIO-Europe 2025, particularly in relation to expanding its pipeline and advancing its immunomodulatory therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Tiziana Life Sciences plc (NASDAQ: TLSA).
NASDAQ: TLSA
TLSA Trading
-4.69% G/L:
$1.22 Last:
67,692 Volume:
$1.27 Open:
